Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Wasp Venom May Give Antibiotics More Sting

Scientists at the Massachusetts Institute of Technology (MIT) have developed an antimicrobial peptide (AMP) that is derived from a 12 amino acid toxin produced by a species of South American wasp. The team used a rational peptide design strategy to fine tune t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists at the Massachusetts Institute of Technology (MIT) have developed an antimicrobial peptide (AMP) that is derived from a 12 amino acid toxin produced by a species of South American wasp. The team used a rational peptide design strategy to fine tune the structure and properties of the wasp peptide, and generate an AMP candidate that was nontoxic to human cells at doses used to completely clear infections in mice caused by the bacterium Pseudomonas aeruginosa, a common cause of respiratory and urinary tract infections in people.

“After four days, that compound can completely clear the infection, and that was quite surprising and exciting because we don’t typically see that with other experimental antimicrobials or other antibiotics that we’ve tested in the past with this particular mouse model,” said Cesar de la Fuente-Nunez, Ph.D., a researcher at the MIT Synthetic Biology Center’s Synthetic Biology Group. “We’ve repurposed a toxic molecule into one that is a viable molecule to treat infections. By systematically analyzing the structure and function of these peptides, we’ve been able to tune their properties and activity.”

The researchers reported on their research in Nature Communications Biology, in a paper titled “Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates.”

Drug-resistant infections represent a growing global health concern. Each year in developed countries including the U.S. about 2 million people become infected with antibiotic-resistant bacteria, resulting in at least 23,000 deaths, the authors write. Antimicrobial peptides represent a promising alternative to traditional antibiotics for treating drug-resistant infections, as they offer effective strategies against difficult-to-treat infections including a group of organisms known as the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp).

AMPs also offer “a unique diversity” of peptide sequences, and while molecules with certain basic sequences have been selected through evolution, making even minor changes to these sequences offers “unprecedented biological function,” the researchers write.

Wasps, bees, spiders, and scorpions are among the insects and arachnids that produce a class of AMPs known as linear amphipathic AMPs, which work by disrupting bacterial cell membranes. The South African social wasp Polybia paulista produces a variety of peptides in its venom, including a 12-residue cationic amphipathic AMP, polybia-CP (Pol-CP-NH2), which takes on a helical structure when it comes into contact with the membranes of microorganisms. “Pol-CP-NH2 is a chemotactic peptide from the venom of a tropical species of wasp that presents 12 residues typical of peptides found in these wasp species,” the authors explained.

Working with colleagues in the U.S and Brazil, the MIT team reasoned that the peptide was small enough to allow them to manipulate the residues and generate variants that could be tested for antibacterial potency, but without harming human cells.

The team’s first step was to create a few dozen variants of the polybia–CP peptide and measure the effects that the changes had on features such as helical structure and hydrophobicity, which is a key determinant of peptide interaction with membranes. These initial variants were tested against Gram-negative and Gram-positive bacterial strains and different fungi, so that their structures and physicochemical properties could be compared with antimicrobial potency.

The structure-activity relationships identified then helped to direct another round of peptide design, through which the scientists optimally changed the proportion of hydrophobic amino acids and positively charged amino acids, while conserving a cluster of amino acids that were required for the molecules’ overall function.

The resulting peptides were then tested for efficacy against a larger panel of Gram-positive and Gram-negative bacteria, and against the fungal strains. The peptides were also evaluated for stability and for toxicity against laboratory-grown human kidney cells. Promising peptides from both rounds of design were then evaluated in an in vivo mouse model of Pseudomonas aeruginosa skin infection. Of the peptides tested, the most potent and nontoxic to the mice completely cleared the infection after just four days.

“Our study is an example of how to design small cationic amphipathic peptides to optimize biological activities and selectivity,” the authors stated. “… we describe a systematic structure-activity relationship design approach aimed at revealing the sequence requirements for antimicrobial activity of a natural wasp venom AMP and several of its derivatives. Through single-residue substitutions guided by identified physicochemical activity determinants, we generated peptide antibiotics with anti-infective potential in a mouse model.”

The researchers are continuing to create peptide variants that might be effective antimicrobial candidates at even lower doses, and hope that their basic approach might also be used to optimize other peptides. “We envision that the principles and approaches exploited here can be applied to other structure-activity studies in order to rationalize and better understand the role of physicochemical features and which approaches fit better to each family of peptides,” they stated.

Dr. de la Fuente-Nunez will be joining a faculty at the University of Pennsylvania next year and plans to apply the same approach to other types of naturally occurring antimicrobial peptides. “I do think some of the principles that we’ve learned here can be applicable to other similar peptides that are derived from nature,” he said. “Things like helicity and hydrophobicity are very important for a lot of these molecules, and some of the rules that we’ve learned here can definitely be extrapolated.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What are functional peptides?

Conventional pharmacological studies on spices have traditionally focused on secondary metabolites like polyphenols, alkaloids, and terpenes. More recently, food science research has also examined spice proteins and their enzymatic hydrolysates, using proteomic methods such as liquid chromatography–tandem mass spectrometry (LC-MS/MS) to identify short bioactive peptide sequences released from larger precursor proteins.6 Once released during food processing, fermentation, or gastrointestinal digestion, these functional peptides can act as metabolic regulators, antimicrobials, or antioxidants.1 Functional peptides refer to specific protein fragments that, once released from their parent proteins, exert biological activities.1,2 In the context of foods, these activities are most often demonstrated using in vitro biochemical or cell-based assays, and their physiological relevance depends on bioavailability and dose.2 Unlike intact proteins, which can have the potential to be allergenic or difficult to absorb due to their complex tertiary structures, functional peptides may exhibit improved bioaccessibility, and some small peptides can cross the intestinal epithelial barrier via peptide transport systems. However, absorption efficiency varies substantially by peptide sequence and digestive conditions.6 Nutriomics and mechanistic investigations have established that the bioactivity of a peptide is dictated by its physicochemical properties, particularly its amino acid composition, molecular weight, and net charge. For example, the presence of hydrophobic amino acids like proline, leucine, and valine often correlates with high antioxidant and enzyme-inhibitory activity.2,3 Smaller peptides, typically those less than three kilodaltons (kDa) in size, exhibit greater stability against proteolytic degradation in the gastrointestinal tract.3 Moreover, cationic peptides are particularly effective as antimicrobial agents through their electrostatic interactions with bacterial membranes.3

Source: www.news-medical.net ↗
02What was this study about?

It has been noted in around 20 percent of the world population suffers from some form of pain or the other. In many individuals, pain may be relieved initially with pain medications, but soon tolerance develops, and there is a decrease in the efficacy of pain relievers. One of the main symptoms of IBS seen commonly in many sufferers is chronic abdominal pain. Professor Lewis said, "All pains are complex, but gut pain is particularly challenging to treat and affects around 20 percent of the world's population. Current drugs are failing to produce effective pain relief in many patients before side effects limit the dose that can be administered." Professor Brierley echoed this statement saying, "Internal organs have a complex network of sensory nerves that have a wide array of voltage-gated ion channels and receptors to detect stimuli... The hypersensitivity of these nerves in disease often contributes to the development of pain."

Source: www.news-medical.net ↗
03What was done in this study?

In the study, published in Scientific Reports, the researchers built on their earlier discovery of the peptide called AC253. This compound was tested in mice with AD. It was found to block the attachment of beta-amyloid to a brain cell receptor called the amylin receptor, and thus inhibit its toxic effects, as shown by an improvement in spatial memory. However, it is difficult to administer this compound because it doesn’t cross the blood-brain barrier in large amounts, and is quickly broken down in the blood. The dosage must therefore be massively increased, pushing up the amounts required for efficacy and increasing the difficulty of administration, besides enhancing the chances of an immune reaction. One way out is to convert the formulation into a pill rather than an injectable form. The complex structure of AC253 makes this difficult as well. Instead, the team devised an ingenious solution. They cleaved the compound into smaller amylin peptides, or chains of 12-14 amino acids, and tested each for its anti-amyloid activity in old mice which showed signs of AD. In this way, they found two short peptides that had the same effects as the larger compound. In particular, the researchers identified a segment that was common to both peptides, namely, SQELHRLQTY.

Source: www.news-medical.net ↗
04What is nisin?

Some bacterial species produce antimicrobial peptides known as bacteriocins that have been used in the food industry as preservatives. For example, nisin, which is produced by Lactococcus lactis, has broad-spectrum bactericidal activity and has been used as a food preservative throughout the world. Nisin is effective in controlling Gram-positive bacteria such as Clostridioides difficile. In combination with other compounds like ethylene diamine tetra-acetic acid and cinnamaldehyde, nisin has been effective in controlling enterotoxigenic Gram-negative bacteria such as Escherichia coli. Previous studies have used chicken and mouse models to demonstrate the in vivo efficacy of nisin on the microbiome, whereas nisin efficacy has been proven in ex vivo experiments on the human microbiome. To date, no studies have assessed the in vivo effects of nisin in large mammals.

Source: www.news-medical.net ↗
05What is the concept of the immune self, and how has it evolved over the decades?

Adaptive immunity is the ability of specific lymphocytes to differentiate between self and non-self (foreign) antigens and defend the body by selectively destroying non-self-peptides. This concept is possibly the most crucial factor in several immunological medical domains and is increasingly being explored across cancer immunotherapy, vaccine design, pathogen identification, and autoimmune disorders (including allergies). A growing body of literature elucidates the importance of peptides, short amino acid chains linked via peptide bonds, in providing the adaptive immune system with the information required to effectively distinguish between self and non-self particles. This has resulted in the proposal of the ‘immune self’ concept, which postulates that self-similarity is a fundamental determinant of immune recognition. First introduced by Frank MacFarlane Burnet in 1949, the immune self-concept and its sister, the self-nonself theory, have substantially evolved over the decades. Initially driven by observations from Medawar’s early transplantation experiments, Nils K. Jerne (1974; eigen-behavior theory), Polly Matzinger (1994; danger theory), and most recently, evidence from research conducted independently by Waldmann, Mitchison, and Janeway has refined the immune self-concept from ‘all body elements are self, and foreign elements are non-self’ to the most recent ‘infectious non-self (foreign and usually harmful) versus noninfectious self (safe) elements.’

Source: www.news-medical.net ↗
comparison

Comparisons

Side-by-side pages for commonly compared peptides and research compounds.

Source: peptideuniv.com
Research context

Read sources and limitations before applying a claim.

Longevity, Performance & Obesity Research

A research peptide formulation developed to investigate metabolic regulation, mitochondrial function, and nutrient-sensing pathways.

Source: mypeptidematch.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →